Fluidigm

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Findings in Nature Communications Provide Insights That May Help Guide Patient Care

CyTOF and Maxpar Direct Technologies Utilized in Study Characterizing Immune and Inflammatory Responses in Pregnant Women Infected with SARS-CoV-2

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor event:

Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit

Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q2 2021 Results - Earnings Call Transcript

Fluidigm Corp's (NASDAQ: FLDM) second-quarter revenues grew 19% Y/Y to $31 million, edging out analysts' average expectation of $30.57 million. Base product and service revenue excluding COVID-19 testing revenue were $26.9 million, up 33% Y/Y, while its service revenue increased 29% to $6.6 million.

Fluidigm Q2 Earnings Ahead Of Street Expectations, But Sees Lower Revenues From COVID-19 Products

CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis.

Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine

Collaboration Focusing on Advancing CRO Capabilities in Drug Development Utilizing the Hyperion Imaging System Collaboration Focusing on Advancing CRO Capabilities in Drug Development Utilizing the Hyperion Imaging System

Fluidigm Announces Collaboration Agreement with Imaging CRO ImaBiotech to Increase Biopharma Access to Imaging Mass Cytometry

Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development

Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision Medicine

Fluidigm Corp (NASDAQ: FLDM) stock is trading higher in the premarket on a report that the Company is considering a sale. According to a Bloomberg report, the medical technology firm is working with an adviser to see interest from possible buyers.

Fluidigm Stock Shoots Higher On Bloomberg Report Of Exploring Potential Sale

SOUTH SAN FRANCISCO, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the market.

Fluidigm Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

Fluidigm Corporation is a leading global developer of life sciences instruments and consumables for use in research, diagnostics, and clinical applications. Fluidigm designs, manufactures, and markets a variety of instruments, consumables, reagents, and software from its two major technologies, CyTOF® Technology and Microfluidics Technology.

Fluidigm Corporation: Discounted Life Sciences Instrument Developer Offers Compelling Entry Point

A New Platform to Simplify Deep Profiling of the Human Immune System A New Platform to Simplify Deep Profiling of the Human Immune System

Next-Generation CyTOF XT Redefines Cytometry with Advances in Automation, Throughput, Time to Results and Total Cost of Ownership

FLAMIN-GO Project Seeks to Develop Organ-on-a-Chip Technology for Clinical Trials in Rheumatoid Arthritis Therapy FLAMIN-GO Project Seeks to Develop Organ-on-a-Chip Technology for Clinical Trials in Rheumatoid Arthritis Therapy

Imaging Mass Cytometry Utilized by Global Consortium Focused on New Precision Medicine Approaches for Treatment of Rheumatoid Arthritis

SOUTH SAN FRANCISCO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company's management will participate in several upcoming investor conferences and provide updates on the company's business strategy and growth plans.

Fluidigm to Present at Upcoming Investor Conferences

The stock price of Fluidigm Corporation (NASDAQ: FLDM) increased by 17.56%. This is why it happened.

FLDM Stock: 17.56% Increase Explanation

SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will host a virtual investor event that will showcase competitive advantages of CyTOF® technology, preview a new product that will enhance the capabilities of a Fluidigm mass cytometry platform, and provide updates on the company's innovation pipeline and key customer relationships.

Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time

Fluidigm Corporation's (FLDM) CEO Chris Linthwaite on Q1 2021 Results - Earnings Call Transcript

Shares of Fluidigm (NASDAQ:FLDM) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 15.38% year over year to ($0.15), which missed the estimate of ($0.14).

Fluidigm: Q1 Earnings Insights

Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to Therapies Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to Therapies

Data Published in Nature Communications Demonstrate the Power of Fluidigm's CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report first quarter 2021 financial results on Thursday, May 6, 2021, after the close of the market.

Fluidigm Announces Conference Call and Webcast of First Quarter 2021 Financial Results

Guardant Health Inc

Nano-X Imaging

Innovation is risky, and these companies are all in.

3 Extraordinary Diagnostics Stocks for 2021

The FDA has granted Emergency Use (EUA) approval for Fluidigm Corporation's (NASDAQ: FLDM) AZOVA COVID-19 test collection kit for use with the company's Advanta Dx SARS-CoV-2 RT-PCR Assay on its Biomark HD platform. The kit is authorized for at-home self-collection by prescription only for individuals suspected of COVID-19 infection.

Fluidigm Gets EUA Nod For Home Sample Collection Kit For Advanta COVID-19 Assay

The company reported disappointing fourth-quarter results.

Why Fluidigm Stock Is Sinking Today

Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q4 2020 Results - Earnings Call Transcript

Fluidigm (FLDM) delivered earnings and revenue surprises of -225.00% and -11.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Fluidigm (FLDM) Reports Q4 Loss, Misses Revenue Estimates

Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million

News for Fluidigm Stock (FLDM)